Regulatory alerts NICE guidelines
Regulatory Alerts, Oncology, Genitourinary cancers, Oncology Room

Abiraterone not recommended for newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

The cost-effectiveness estimates of either abiraterone in combination compared with ADT alone or with docetaxel plus ADT for the whole population are higher than what NICE considers cost effective, according to final guidance.

Go to the profile of OnMedica
OnMedica
Editorial team, Wilmington Healthcare
Published

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in

Sorry, we need to confirm your details before you can access this content.

If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact customer.services@onmedica.com.

You may also be interested in...